Please select the eligibility criteria that correspond to the clinical trial below.
Title: The Van Gogh-PE Trial, a Multicenter, International, Randomized, Open-Label, Assessor-Blind, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Weekly Subcutaneous SR34006 With the Combination of (LMW)Heparin and Vitamin K Antagonist (VKA) in the Treatment of Acute Symptomatic Pulmonary Embolism
Brief Summary: Patients who have a pulmonary embolism (blood clot in the lung) will be treated in this study. The purpose of the study is to compare the safety and effectiveness of a new injectable anticoagulant (blood-thinning) drug, SR34006, with the standard way of treating a pulmonary embolism. The standard treatment includes injections or infusions of an anticoagulant drug, (LMW)heparin, for about a week followed by anticoagulant tablets (warfarin or acenocoumarol) which are taken by mouth.

Assignment to either SR34006 or (LMW)heparin plus warfarin or acenocoumarol will be purely by chance and will be known by both patients and their doctors.


Options:
A: Inclusion Criteria:

* Confirmed acute symptomatic Pulmonary Embolism (PE) with or without concomitant Deep Vein Thrombosis (DVT)
* Written informed consent

Exclusion Criteria:

* Legal lower age limitations (country specific)
* Thrombectomy, insertion of a caval filter, or use of a fibrinolytic agent to treat the current episode of PE
* Other indication for VKA than PE/DVT
* More than 36 hours pre-randomization treatment with therapeutic dosages of (LMW)heparin or initiation of VKA treatment prior to randomization
* Participation in another pharmacotherapeutic study within the prior 30 days
* Creatinine clearance \<10 mL/min, severe hepatic disease, or bacterial endocarditis
* Life expectancy \<3 months
* Active bleeding or high risk for bleeding
* Uncontrolled hypertension: systolic blood pressure \>180 mm Hg or diastolic blood pressure \>110 mm Hg
* Pregnancy or childbearing potential without proper contraceptive measures or women who are breastfeeding
* Any other contraindication listed in the labeling of warfarin, acenocoumarol, unfractionated heparin, enoxaparin, or tinzaparin
B: Subject Inclusion Criteria In order to be enrolled in the study, subjects must meet all of the inclusion criteria as listed below.

1. Consecutive patients undergoing isolated or redo isolated CABG
2. Patients must provide written informed consent
3. Patients must agree to comply with study procedures for the entire length of the study.
4. Must be 18 years old or greater.

Subject Exclusion Criteria Any subject that meets any of the exclusion criteria listed below at baseline will be excluded from study participation.

1. Patients with medical history that requires chronic anticoagulation with unfractionated heparin or coumadin or LMWH or heparinoids (i.e. previous DVT, pulmonary embolism, atrial fibrillation, heart valve replacement)
2. Patients with contraindications to anticoagulation (coagulopathy e.g, INR\>/=1.5, generalized bleeding disorders, peptic ulcer disease, hemorrhagic or ischemic stroke, etc within last 3 months)
3. Patients who are unable to undergo a doppler ultrasound of the lower extremities
4. Renal insufficiency (creatinine clearance \< 30 mL/min)
5. Patients who have a body weight \< 50 kg
6. Patients receiving continuous (indwelling) epidural
7. Physician diagnosed acute or chronic hepatic failure
8. Pregnancy
9. Patients with life expectancy \< 6 months
10. Platelet count below 100,000/ mm-3
11. History of documented VTE within last 3 months.
12. Acute bacterial endocarditis
13. Cerebral metastasis or abscess
14. Inability to consent
15. Refusal by treating physician
C: Inclusion Criteria:

* Confirmed acute symptomatic DVT of the lower limbs

Exclusion Criteria:

* Severe concomitant diseases (e.g. renal failure, hepatic failure, uncontrolled hypertension)
* Active bleeding or high risk for bleeding.
* Pregnancy or childbearing potential without proper contraceptive measures.
* Breastfeeding
* Known allergy to idraparinux, SSR126517E, or egg proteins
* Indication of prolonged anticoagulation for other reason than DVT of the lower limbs
* Symptomatic pulmonary embolism (PE)
* Life expectancy \< 6 months.
D: Inclusion Criteria:

* Patients with SRI or MiRI undergoing orthopedic surgery of the lower limbs

Exclusion Criteria:

* Patients who are on hemodialysis or are scheduled to undergo hemodialysis during the study period
* Patients who are at a significantly high risk for bleeding or thromboembolism
* Patients who are receiving another antithrombotic therapy and are unable to suspend the therapy
* Patients who have evidence of hepatic function test abnormalities

Answer: A